PBAC's latest decision on Garadacimab: Recommended with restriction (2024). Considered for Routine prevention of hereditary angioedema (HAE) attacks in adult and adolescent patients aged 12 years and older with HAE Types I and II.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adult and adolescent patients aged 12 years and older with hereditary angioedema Types I and II who experience at least 12 treated acute HAE attacks within a 6-month period.
Therapy area
Rare disease
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Other
Key trials
VANGUARD, HELP
Comparator
lanadelumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated.